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Aim: To evaluate the impact of a medical education course (MEC) on the behaviour of general
practitioners (GPs) to treat asthma and allergic rhinitis (AR).
Methods: Data on 1820 patients (mean age 41yrs 17yrs) with asthma or AR were collected by
107 Italian GPs: 50% attended a MEC and 50% didn’t (group B). The adherence for AR and
asthma treatment was evaluated according to ARIA and GINA guidelines (GL).
Results: AR and asthma were diagnosed in 78% and 56% of patients; 34% had concomitant AR
and asthma. Regardless of the MEC, the adherence to GL was significantly higher for AR than
for asthma treatment (52 versus 19%). Group B GPs were more compliant to ARIA guidelines
in the treatment of mild AR, whereas group A were more compliant in the treatment of
moderateesevere AR; the adherence didn’t differ between the groups for AR patients with co-
morbid asthma. Adherence to GINA GL for asthma treatment did not differ between GPs of
groups A and B, independently from concomitant AR. Though insignificantly, group A were more
compliant to GINA GL in the treatment of patients with only severe persistent asthma (63
versus 46%) as group B were for patients with severe persistent asthma and concomitant AR.
Conclusions: GPs often tend to treat patients independently from GL. The impact of a single
MEC did not improve adherence to GL in treating less severe AR and asthma patients, while
there was a trend towards the opposite attitude in more severe AR patients without concom-
itant asthma.
ª 2012 Elsevier Ltd. All rights reserved.
S. Baldacci et al.Introduction
Allergic rhinitis (AR) and asthma are inflammatory condi-
tions of the respiratory tract that often coexist. AR affects
10e20% of people from all countries, ethnic groups,
conditions and ages, causing major illness and disability
worldwide, with substantial socioeconomic impact.1e3
Asthma affects about 300 million individuals with preva-
lence rate ranging from 1 to up to 18% of the general
population worldwide.4 In Italy, among the general pop-
ulation asthma prevalence is about 6%,5 among young
adults 8.9%,6 and, respectively, 9.3% and 10.3% among
children and adolescents.7
There is well-documented evidence of an important
overlap between AR and asthma. It was found that about
40% of AR patients had asthma, and 30e80% of asthmatic
patients reported AR.8 In Italy, about 60% of asthmatics
reported allergic rhinitis, too.6 It was even hypothesized
that AR and asthma represent a continuum of the same
disease.9
The correct management of asthma and rhinitis could be
ensured by following international GINA (Global Initiative
for Asthma) and ARIA (Allergic Rhinitis and its Impact on
Asthma) guidelines (GL) published by the World Health
Organization. ARIA GL stress the importance of the links
between rhinitis and asthma and provide recommendations
about best management options for most patients in most
situations.10 These GL have been developed to help physi-
cians in ameliorating patients management by presenting
them with optimal clinical practices based on a systematic
review of current evidence about treatment options for
asthma and allergic rhinitis. GINA and ARIA GL have been
developed to improve the quality of care for patients and
reduce the public health burden associated with these
diseases. The GL specify that effective long-term control of
disease may be achieved for each disease severity level by
selecting appropriate medications, treating asthmaattacks, identifying and avoiding asthma triggers,
educating patients to manage their condition, and by
regular monitoring of the disease.
However, there is evidence that GL recommendations
are often not applied within the clinical practice11e14 and
this might result in under or overtreatment of patients.
Difficulty in the implementation of GL in clinical practice
may be due to several factors, including poor communica-
tion within the doctorepatient relationship, structural
limitations of the National Health Systems, treatment
duration, or the patients’ own beliefs about medications.
General practitioners (GPs) are among the first healthcare
professionals to whom patients with asthma or rhinitis should
refer for their symptoms and, therefore, GPs are encouraged
to understand and use GL. Programs of Continuing Medical
Education (CME) should improve both the medical knowledge
and the adherence to GL, although studies on their effec-
tiveness have shown conflicting results.15e18 CME programs
differ largely around the world. They are established in the
U.S. and many European countries since many years; in Italy,
they became mandatory by law in 2002.
In spite of the high burden of asthma and AR in the
general population and the important role played by GPs in
the management of such diseases, there are few evalua-
tions so far concerning data provided directly by GPs.
The ARGA study (the Italian acronym for ‘Allergopatie
Respiratorie: studio di monitoraggio delle linee guida GINA e
ARIA’), funded by the Italian Drug Agency (AIFA), was carried
out between March 2007 and February 2010. The general aim
was to monitor correspondence between scientific knowl-
edge based on the World Health Organization GINA19 and
ARIA2 GL for asthma and allergic rhinitis management and
applicability in clinical practice.
The ARGA study included several sub-projects related to
different cross-sectional or longitudinal studies with
specific aims, and it was framed in four research sectors:
(1) observational studies; (2) drug surveillance; (3)
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and pharmacoeconomy.
The present study relies on the sub-project of the ARGA
study titled ‘Observational study on Italian General
Practitioners’.
Aim of the present report was to evaluate the impact of
an educational program on GPs behaviour concerning: (1)
drug prescription, for AR and asthma, and (2) prescription
adherence to ARIA and GINA GL.
Methods
Population
This prospective study was performed by the Pulmonary
Environmental Epidemiology Unit of the CNR Institute of
Clinical Physiology (Pisa, Italy) with randomly enrolled GPs
and their patients, residing in 20 Italian provinces distrib-
uted in three macro-areas (North, Centre, South-Islands).
The number of GPs invited to participate was chosen based
on density of the residing Italian population.
Recruitment was performed via mail. Considering a 30%
drop out mean rate and a minimum number expected of 120
GPs, 180 GPs were invited to participate in the study. 89%
of GPs (nZ 107) agreed to participate out of the minimum
number expected.
GPs were invited to select all their patients with
asthma and/or AR, with a pharmacological treatment or
presence of asthma-like/AR symptoms in the last 12
months. Since in Italy under the age of 14 years children
are in charge of family paediatricians and not of GPs, male
and female Italian citizens aged 14 years and over were
considered eligible subjects for our study. Subjects
deemed unable to collaborate in the survey, and those
permanently hospitalized or living in nursery homes, were
excluded.
Participating patients provided “ex-ante”written informed
consent for the purposes of the study (participation in the
study, anonymous management of individual and collective
data and anonymous publication of the research results).
Before the beginning of data collection, GPs were
randomly divided in two groups (A and B). After the
randomization and prior to the beginning of data collection,
group A GPs (nZ 54, 50.5%) attended a medical educa-
tional course on ARIA and GINA GL. Group B GPs (nZ 53,
49.5%) did not participate in the course, and represented
the control group. Two editions of the course were held,
one at the end of March (Milan) and the other at the
beginning of April (Rome), in order to facilitate the
participation of GPs residing in the national territory.
The course lasted 8 hours and dealt with the following
topics: epidemiology of respiratory allergic diseases, ARIA
and GINA GL (diagnosis, severity, control and drugs
prescription), patients and caregiver education, quality
evaluation of allergenic extracts utilized in specific immu-
notherapy, drug surveillance, prescriptions appropriateness
and pharmacoeconomy, methodological aspects of the
study.
The study protocol, patient information sheet and
consent form were approved by the Ethic Committee of
University-Hospital of Pisa (Azienda Ospedaliero-Universitaria Pisana) on October 13, 2006 (Prot. no. 37710
of October 25, 2006).
Data collection
GPs reported information on diagnosis, disease severity and
treatment of their patients filling in a specifically formu-
lated questionnaire.
Concerning diagnosis and severity level, we considered
the following questions:
1. ‘What kind of diagnosis have you made for your
patient?’ (AR, asthma or both).
2. ‘Have you assessed the severity level of AR/ asthma of
your patients?’ (Yes, No).
3. If Yes, ‘What is the diagnosed severity level of AR /
asthma?’ (Mild intermittent, mild persistent, moder-
ateesevere intermittent, moderateesevere persistent
for AR2; intermittent, mild persistent, moderate
persistent, severe persistent for asthma.19
For some patients GPs did not answer the first question,
even though they provided information on the severity
level. Thus, to minimize missing information, a patient was
classified as having AR and/or asthma according to the
reported diagnosis and/or severity level.
Statistical analyses
Statistical analyses were carried out using the Statistical
Package for Social Sciences (SPSS), rel. 13.0. Used routines
were frequency distribution, cross tabulations, and non-
parametric tests of ManneWhitney.
The therapeutic groups considered in statistical analyses
to assess the correct adherence to the guidelines were those
listed in ARIA GL2 for treatment of AR and in GINA GL4 for
treatment of asthma. The adherence to GL was evaluated
according to asthma and AR classification (Table 1).
To assess the impact of the preliminary educational
course on prescribing adherence to GL, we compared the
behaviour of group A GPs to that of group B GPs. For these
comparisons, chi-square test was used. A two-tailed test
with a 5% level of significance was used for analysis.
Seventeen GPs of group A and 17 GPs of group B should
be enrolled to yield a 80% of power to detect, at the 5%
level of significance, a 10% difference between the groups
in the proportion of disease control obtained with the GL
application; a higher number of GPs participated (54 GPs of
group A and 53 GPs of group B) permitting us to yield 90% of
power to detect, at the 5% level of significance, a 10%
difference between the groups in the proportion of disease
control obtained with the GL application.
Results
GPs participating in the study (nZ 107) were 79.3% male;
43.1% resided in the North macro-area, 18.6% in the Centre,
and 38.2% in the South-Islands area.
Table 2 reports general characteristics, diagnosis, and
severity level of patients enrolled in this study. GPs collected
data on 1820 patients aged 14e90 (median age 40 yrs), 835
Table 1 Summary of recommendations for allergic rhinitis (AR) and asthma treatment according to ARIA2 and GINA4 guide-
lines, respectively.
Suggested therapy
ARIA e AR classification
Mild intermittent Anti-H and/or decongestants or LTRAa
Mild persistent Anti-H and/or decongestants or NCS or Chromones or LTRAa
Moderateesevere intermittent Anti-H and/or decongestants or NCS or Chromones or LTRAa
Moderateesevere persistent NCS or anti-H or LTRAa and decongestant/anticholinergics/SCS
GINA e asthma classification
Intermittent No treatment or SABA
Mild persistent ICS or Theophyllines or Chromones or LTRA
Moderate persistent ICS or ICSþ LABA/Theophyllines/LTRA
Severe persistent ICSþ LABAþ Theophyllines/LTRA/SCS
Anti-H, antihistamines; NCS, nasal corticosteroids; LTRA, leukotriene receptor antagonists; SCS, systemic corticosteroids; SABA, short-
acting b2-agonists; ICS, inhalant corticosteroids; LABA, long-acting b2-agonists.
a For AR patients with concomitant asthma.
780 S. Baldacci et al.male (46%). Of these, 78% had AR, 56% had asthma and 34%
hadasthmaþ AR. In 13%ofpatientsGPs reported theyhadnot
assessed severity level of the disease (12% of AR patients and
7% of asthmatics). As for disease severity,most of the patients
with AR (72.8%) were diagnosed by GPs as having a mild form
(46.2% mild intermittent and 26.6% mild persistent) and most
asthma patients (73.8%) had an intermittent/mild persistent
form.Only 7% of patients hadmoderateesevere persistent AR
and 3.6% had severe persistent asthma.
AR treatment
Antihistamines (anti-H) and nasal corticosteroids (NCS)
were the most prescribed drugs for AR treatment, regard-
less of GPs group, and whether these drugs were prescribed
as single or combined therapy (Table 3).
Prescribing patterns differed significantly in patients with
only AR. In patientswithmild intermittent AR, groupBmostly
prescribed anti-H as monotherapy; in mild persistent AR,
group A prescribed other drugs (sistemyc corticosteroids) as
monotherapy; in moderateesevere intermittent AR, group B
GPs mostly prescribed anti-H as monotherapy, while group A
GPs prescribed the combination of anti-Hþ NCS.
Prescribing patterns in patients with ARþ asthma did not
differ significantly in group A and B GPs with the exception of
anti-Hþ other drug/s that were more prescribed in patients
with mild intermittent AR by group A GPs.
Asthma treatment
Generally, inhaled corticosteroids (ICS)þ long-acting b2-
agonists (LABA) or short-acting b2-agonists (SABA) as mon-
otherapy were the most frequently prescribed medicines in
patients with asthma (Table 4).
There were significant differences between the two
groups in the treatment of mild or moderate persistent
asthma without AR co-morbidity. Group A GPs were more
likely to treat these patients with combined therapies of
LABAþ ICS or LABAþ other; instead, group B GPs more
frequently prescribed LABA as monotherapy and associa-
tions of LABA with SABA.Prescribing patterns for the treatment of asthmaþ AR
did not differ significantly between group A GPs and
group B GPs, except for the few patients with severe
persistent asthma: both GPs prescribed a polipharmacy
treatment with LABA, but group B GPs included also SABA
prescription.
Prescription adherence to GL
In general, prescription adherence to GL was significantly
higher for AR than for asthma (52.4 versus 19.4%, p< 0.001)
regardless of the educational course.
In general, GPs who did not attend the educational
course were significantly more compliant to ARIA GL than
those who did (Fig. 1). Sensitivity analysis for severity
levels showed that group B GPs treated patients with mild
AR more appropriately, reaching a significant difference
in the mild intermittent subgroup. Group A GPs were
instead more compliant to ARIA GL regarding prescrip-
tions for persistent AR, significantly for the moder-
ateesevere subgroup. Considering patients with asthma
co-morbidity, there was no difference in the prevalence
of adherence to ARIA GL for AR treatment between the
two GPs groups.
There were no significant differences in prescription
adherence to GINA GL for asthma among group A GPs and
group B GPs, even in patients with concomitant AR (Fig. 2).
Although insignificantly, group A GPs were more compliant
to GINA GL than group B GPs for patients with only severe
persistent asthma (63 versus 46%), whereas an opposite
trend was shown for severe persistent asthma patients with
concomitant AR (57 versus 67%).
The time lapse between the educational course and data
collection did not affect in any way prescriptive appropri-
ateness by group A GPs (ManneWhitney non-parametric
test pZ 0.44 for AR and 0.54 for asthma).
Discussion
Regardless of the preliminary medical education course
(MEC), GPs were more adherent to ARIA GL for AR
Table 2 Characteristics of the sample.
N (valid %)
Sample size 1820
Male gender 835 (45.8)
Age, years
Mean SD (Median) 40.8 16.9 (40.0)
Range 14e90
General practitioner
Group Aa 1000 (54.9)
Group B 820 (45.1)
Smoking status
Never smokers 1107 (60.8)
Former 287 (15.8)
Current 213 (11.7)
Unanswered (nZ 213, 11.7%)
Condition
Allergic rhinitis (AR) 1379 (77.9)
Only-AR 776 (43.8)
Asthma 995 (56.2)
Only-asthma 392 (22.1)
ARþ asthma 603 (34.0)
Missing (nZ 49, 2.7%)
AR classification (nZ 1379)
Mild intermittent 553 (46.2)
Mild persistent 318 (26.6)
Moderateesevere intermittent 242 (20.2)
Moderateesevere persistent 84 (7.0)
Not evaluatedb (nZ 159, 11.5%)
Missing (nZ 23, 1.7%)
Asthma classification (nZ 995)
Intermittent 436 (48.5)
Mild persistent 227 (25.3)
Moderate persistent 204 (22.7)
Severe persistent 32 (3.6)
Not evaluated (nZ 69, 6.9%)
Missing (nZ 27, 2.7%)
a Attending the preliminary medical educational course.
b Severity level not evaluated by GPs.
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adherence to GL significantly increased according to
disease severity, in both groups A and B GPs.
There has been considerable debate and widespread
skepticism about the impact of continuing medical educa-
tion on physicians’ performance in the practice setting. In
the U.S., disseminating multidisciplinary GL showed no
clear effect on prescribing behaviour, even though GPs
were more intensely involved in their development.20 In
Mexico, 40% of physicians did improve their prescribing
practices after an interactive educational workshop on
rhino-pharyngitis treatment, however more than 40% did
not.21 A study performed in France to determine the impact
on medical practices of ARIA GL knowledge, found that
there was no significant difference of first-line treatmentstrategy for asthma between physicians claiming to know
ARIA GL and those who did not.17
Accordingly, in our study we noted only few differences
in prescription behaviour among group A GPs (attending the
educational course) and group B GPs (not attending the
course); in particular, group B GPs were more compliant to
ARIA GL in the treatment of mild AR, whereas group A GPs
tended to be more compliant in the treatment of moder-
ateesevere AR. This behaviour might have been influenced
by pre-existing knowledge about asthma and rhinitis
management of both groups A and B GPs and by the
attendance to other past educational initiatives. Short term
period between the MEC and data collection might also
have negatively affected GL adherence of group A GPs: in
fact, there is evidence that prescribing habits of individual
physicians are quite firmly established and changes might
occur slowly depending on various factors like scientific
papers, specialist recommendations, meetings, colleagues
and patients.22
Thus, exposure to a single educational course did not
improve adherence to GL in treating less severe allergic
rhinitis and asthma patients, while there was a trend
towards the opposite in more severe allergic rhinitis
patients without concomitant asthma.
Indeed, a recent review, concluded that multiple CME
exposures are more effective to maximize retention and
improve physician application of knowledge.15 However,
another recent review which evaluated the impact of CME
on short- and long-term physician practice performance,
indicated that the amount of frequency of exposure to CME
activities appeared to have little effect on behaviour
change.16
AR treatment
Regardless of the education course, the adherence to ARIA
GL was quite low, in accordance with marketing studies,
which show that the majority of GPs do not completely
follow ARIA GL.23
We noted a large use of antihistamines, even as mono-
therapy, to treat patients with moderateesevere persistent
AR, although ARIA GL suggest NCS. Anti-H are more effec-
tive in seasonal than perennial AR, and the treatment with
NCS is preferentially indicated for more severe form of AR
with persistent nasal congestion.
GL adherence increased as AR severity augmented and
reached its peak for moderateesevere persistent AR. This is
a promising finding, since GL-based approach has been
demonstrated more effective than freeform treatment23
for such severity level. Overall, it is a good result that
group A GPs were more compliant than group B GPs to treat
more severe AR. This may indicate a limited validity of the
medical education course in improving adherence to ARIA
GL, regardless of asthma co-morbidity.
Asthma treatment
In general, adherence to GINA GL was low, independently
of the education course. This is not surprising. Several
authors continue to show poor physician’s compliance with
asthma management guidelines in clinical practice,24e26
Table 3 Prescriptions for allergic rhinitis (AR) treatment as reported by general practitioners (GPs) attending (group A) and
not attending (group B) the preliminary medical educational course. Percent prevalence by AR classification based on ARIA
guidelines.
GPs group Mild intermittent Mild persistent Moderateesevere
intermittent
Moderate
esevere
persistent
A B A B A B A B
Only-AR: (N patients) (198) (134) (110) (63) (65) (58) (32) (12)
Anti-H monotherapy 41.9 55.2* 42.7 44.4 18.5 46.6*** 31.3 25.0
NCS monotherapy 8.1 3.7 4.5 1.6 4.6 5.2 e e
Other monotherapy 3.5 1.5 0.9 e* e 1.7 e e
Anti-Hþ NCS 23.7 25.4 27.3 41.3bl 53.8 24.1*** 34.4 41.7
Anti-Hþ other/s 10.6 10.4 16.4 9.5 18.5 20.7 31.3 33.3
ARþ asthma: (N patients) (112) (109) (63) (82) (98) (51) (25) (15)
Anti-H monotherapy 18.8 27.5 22.2 29.3 17.6 13.7 24.0 6.7
NCS monotherapy 8.9 11.0 e 3.7 5.9 9.8 8.0 13.3
Other monotherapy 6.3 5.5 7.9 6.1 2.9 5.9 e 13.3bl
Anti-Hþ NCS 28.6 27.5 25.4 28.0 19.1 29.4 36.0 13.3
Anti-Hþ other/s 21.4 11.0* 23.8 12.2bl 35.3 27.5 24.0 26.7
Anti-H, antihistamines; NCS, nasal corticosteroids
Statistical difference between GPs groups: *p< 0.05; ***p< 0.001; bl (border line) 0.05< p< 0.1.
Table 4 Prescriptions for asthma treatment as reported by general practitioners (GPs) attending (group A) and not attending
(group B) the preliminary medical educational course. Percent prevalence by asthma classification based on GINA guidelines.
GPs group Intermittent Mild persistent Moderate
persistent
Severe
persistent
A B A B A B A B
Only-asthma: (N patients) (67) (57) (39) (58) (45) (54) (8) (11)
SABA monotherapy 19.4 19.3 10.3 3.4 2.2 e e e
ICS monotherapy 9.0 1.8bl 7.7 3.4 e 1.9 e e
LABA monotherapy 1.5 3.5 e 12.1* e e e e
Other monotherapy 4.5 5.3 2.6 5.2 e 1.9 e e
ICSþ LABA 25.4 28.1 41.0 22.4* 26.7 35.2 e 27.3
ICSþ SABA 11.9 8.8 7.7 8.6 4.4 5.6 12.5 e
SABAþ other 9.0 8.8 5.1 6.9 8.9 5.6 e e
LABAþ other 9.0 1.8bl 17.9 6.9bl 31.1 14.8* 25.0 36.4
SABAþ LABAþ other 9.0 21.1bl 5.1 29.3** 26.7 31.5 62.5 36.4
Other not including SABA/
LABA
1.5 1.8 2.6 1.7 e 3.7 e e
Asthmaþ AR: (N patients) (131) (113) (53) (57) (51) (48) (7) (5)
SABA monotherapy 19.1 15.9 1.9 3.5 3.9 e e e
ICS monotherapy 6.1 8.0 1.9 3.5 2.0 e e e
LABA monotherapy 2.3 3.5 1.9 1.8 2.0 e e e
Other monotherapy 5.3 4.4 5.7 1.8 e 2.1 e e
ICSþ LABA 21.4 26.5 20.8 33.3 13.7 25.0 14.3 e
ICSþ SABA 9.2 9.7 5.7 5.3 3.9 4.2 e e
SABAþ other 9.9 5.3 9.4 1.8bl 5.9 10.4 14.3 e
LABAþ other 11.5 12.4 28.3 21.1 39.2 31.3 71.4 20.0bl
SABAþ LABAþ other 12.2 13.3 18.9 26.3 27.5 27.1 e 80.0**
Other not including SABA/
LABA
3.1 0.9 5.7 1.8 2.0 e e e
SABA, short-acting b2-agonists; ICS, inhalant corticosteroids; LABA, long-acting b2-agonists; AR, allergic rhinitis. Statistical difference
between GPs groups: *p< 0.05; **p< 0.01; bl (border line) 0.05< p< 0.1.
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Figure 1 Prevalence of appropriate prescriptions according to ARIA guidelines for allergic rhinitis treatment. Comparison
between general practitioners (GPs) attending (group A) and not attending (group B) the preliminary medical educational course.
Modesev, moderateesevere. Statistical significance: ** p< 0.01, ***p< 0.001.
Medical education and asthma/rhinitis treatment in general practice 783regardless of patients’ characteristics.27 Lack of awareness
or familiarity to GL recommendations, disbelief that
a recommendation will lead to an improved outcome,
difficulties in reconciling patient’s preferences with
guideline recommendations, lack of reminder systems/
counseling materials/consultant support, as well as poor
reimbursement or increased practice costs, and even
increased liability may be self-reported barriers that
undermine the adherence of physicians to clinical practice
GL.28
In the present study, LABA were prescribed as single
therapy to treat at least a few patients, although LABA
should only be used in combination with an appropriate
dose of ICS, because the risk of asthma-related adverse
events, including deaths, increases if LABA are taken as
single medicine. We also found that less than one third2
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Only Asthma
Figure 2 Prevalence of appropriate prescriptions according to
general practitioners (GPs) attending (group A) and not attending(24e30%) of patients with intermittent or mild persistent
asthma were prescribed ICSþ LABA, regardless of asthma
symptoms in the past year. A study performed in the U.S. on
more than 16,000 asthmatics found that slightly less than
40% of patients met the criteria for appropriate prescrip-
tion of ICSþ LABA, and these patients were significantly
more likely to be treated by pulmonologists and allergists
than by GPs.29
On the other hand, our GPs did not use ICS to treat
a large number of patients with persistent asthma. Recent
studies have shown that only a small percentage of patients
received appropriate treatment with ICS.30
Although the use of SABA is recommended only for relief
of symptoms, we found that SABA, in association with other
drugs, were often used as controller medications to treat
persistent asthma.1
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GINA guidelines for asthma treatment. Comparison between
(group B) the preliminary medical educational course.
784 S. Baldacci et al.Similarly to ARIA GL, the adherence to GINA GL tended
to improve as asthma severity increased. In general, the
educational course did not affect prescriptive adherence to
GINA GL, even though other authors have shown effec-
tiveness.18 The only possible indication of an effect of the
MEC comes from the treatment of severe persistent asthma
without concomitant AR, in which group A GPs were more
compliant to GINA GL than group B GPs, although not
significantly (Fig. 2).Limitations of the study
Data on drug prescription patterns only provide limited
information for judging their quality.31
When we started the study, use of leukotriene receptor
antagonists (LTRA) was recommended only for treating AR
patients with concomitant asthma. During the course of our
study, ARIA GL were updated and LTRA were added to the
list of recommended drugs for rhinitis regardless of asthma
co-morbidity.2 When considering this change, adherence
increases only slightly, except for mild intermittent AR
which did not change at all.
Since the prescribed treatment is a result of an
agreement between doctor and patient, some deviations
from the gold standard are to be expected.32 Thus, our
results on the adherence to GL have to be evaluated with
caution.Conclusion
Our results confirm similar studies showing that GPs often
tend to ignore GL. However, there was a trend to improve
adherence to GL when treating more severe patients.
A single medical educational course did not improve
adherence to GL in treating less severe patients.
These findings underscore the need to implement clin-
ical practice guidelines by more effective and innovative
interventions aimed at improving physicians’ compliance.Conflict of interest
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